Abstract
The first reports of disorders that in terms of cognitive and behavioral symptoms resemble frontotemporal dementia (FTD) and in terms of motor symptoms resemble amyotrophic lateral sclerosis (ALS) bring us back to the second half of the 1800s. Over the last 150 years, and especially in the last two decades, there has been growing evidence that FTD signs can be seen in patients primarily diagnosed with ALS, implying clinical overlap among these two disorders. In the last decade pathological investigations and genetic screening have contributed tremendously in elucidating the pathology and genetic variability associated with FTD and ALS. TAR DNA binding protein [TARDBP or TDP-43] and the fused in sarcoma gene [FUS] and their implication in these disorders belong to the most important recent discoveries. FTD and ALS are the focus of this review which aims to: 1. summarize clinical features by describing the diagnostic criteria and specific symptomatology, 2. describe the morphological aspects and related pathology, 3. describe the genetic factors associated with the diseases and 4. summarize the current status of clinical trials and treatment options. A better understanding of the clinical, pathological and genetic features characterizing FTD and ALS will shed light into overlaps among these two disorders and the underpinning mechanisms that contribute to their onset and development. Advancements in the knowledge of the biology of these two disorders will help developing novel and, hopefully, more effective diagnostic and treatment options.
Keywords: ALS, FTD, FUS, motor disease, proteinopathies, TAU, TDP-43, ubiquitin inclusions, FTLD, MAPT, MDD, cognitive dysfunctions, ALSbi, affective symptoms, DLPFC
Current Alzheimer Research
Title: FTD and ALS: A Tale of Two Diseases
Volume: 8 Issue: 3
Author(s): R. Ferrari, D. Kapogiannis, E. D. Huey and P. Momeni
Affiliation:
Keywords: ALS, FTD, FUS, motor disease, proteinopathies, TAU, TDP-43, ubiquitin inclusions, FTLD, MAPT, MDD, cognitive dysfunctions, ALSbi, affective symptoms, DLPFC
Abstract: The first reports of disorders that in terms of cognitive and behavioral symptoms resemble frontotemporal dementia (FTD) and in terms of motor symptoms resemble amyotrophic lateral sclerosis (ALS) bring us back to the second half of the 1800s. Over the last 150 years, and especially in the last two decades, there has been growing evidence that FTD signs can be seen in patients primarily diagnosed with ALS, implying clinical overlap among these two disorders. In the last decade pathological investigations and genetic screening have contributed tremendously in elucidating the pathology and genetic variability associated with FTD and ALS. TAR DNA binding protein [TARDBP or TDP-43] and the fused in sarcoma gene [FUS] and their implication in these disorders belong to the most important recent discoveries. FTD and ALS are the focus of this review which aims to: 1. summarize clinical features by describing the diagnostic criteria and specific symptomatology, 2. describe the morphological aspects and related pathology, 3. describe the genetic factors associated with the diseases and 4. summarize the current status of clinical trials and treatment options. A better understanding of the clinical, pathological and genetic features characterizing FTD and ALS will shed light into overlaps among these two disorders and the underpinning mechanisms that contribute to their onset and development. Advancements in the knowledge of the biology of these two disorders will help developing novel and, hopefully, more effective diagnostic and treatment options.
Export Options
About this article
Cite this article as:
Ferrari R., Kapogiannis D., D. Huey E. and Momeni P., FTD and ALS: A Tale of Two Diseases, Current Alzheimer Research 2011; 8 (3) . https://dx.doi.org/10.2174/156720511795563700
DOI https://dx.doi.org/10.2174/156720511795563700 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Imaging of Soft Tissue Tumors
Current Medical Imaging Magnetically Responsive Paclitaxel-Loaded Biodegradable Nanoparticles for Treatment of Vascular Disease: Preparation, Characterization and In Vitro Evaluation of Anti-Proliferative Potential
Current Drug Delivery Discovery of a Small Molecule Inhibitor of the Interaction Between HIV-1 Proteins and Cellular Cofactors: A Novel Candidate Anti-HIV-1 Drug
Current Chemical Biology New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Recurrence in Bladder Cancer: A Molecular Dead End?
Current Genomics Novel Epigenetic Targets in Lymphoproliferative Disorders
Current Cancer Drug Targets Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Cytomegalovirus US28: A Functionally Selective Chemokine Binding Receptor
Infectious Disorders - Drug Targets Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Natural Flora and Anticancer Regime: Milestones and Roadmap
Anti-Cancer Agents in Medicinal Chemistry The Potential Use of RNA-based Therapeutics for Breast Cancer Treatment
Current Medicinal Chemistry New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease
Current Medicinal Chemistry The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Human Chorionic Gonadotropin: A Model Molecule For Oligopeptide-Based Drug Discovery
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets Targeting Tumors Using Estrogen Receptor Ligand Conjugates
Current Cancer Drug Targets